<DOC>
	<DOCNO>NCT00002130</DOCNO>
	<brief_summary>To examine continue safety tolerability four dose vesnarinone HIV-infected patient complete short-term study ( le 12 month continuous treatment ) drug .</brief_summary>
	<brief_title>A Long-Term , Follow-On Safety Study Four Doses OPC-8212 ( Vesnarinone ) HIV-Infected Persons</brief_title>
	<detailed_description>Patients complete limited duration study ( le 12 month continuous treatment ) vesnarinone protocols FDA 234A FDA 234B current sign symptoms AIDS-defining illness may roll study continue receive regimen vesnarinone 12 month beyond original participation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vesnarinone</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii , candida , mycobacteria . Acyclovir acute treatment herpes . Exclusion Criteria Concurrent Medication : Excluded : Antiretroviral agent , include ddI , ddC , AZT , d4T . Immunosuppressive agent . Investigational HIV drugs/therapies include vaccine . Interferon immunomodulating agent . Corticosteroids ( topical ) . Megestrol acetate . Agents know cause neutropenia . Ganciclovir . Cytotoxic chemotherapy . Concurrent Treatment : Excluded : Radiation therapy . Patients follow prior condition exclude : Poor compliance ( le 80 percent drug take ) Phase I protocol ( FDA 234A FDA 234B ) . Missed one clinic visit Phase I protocol . Prior Medication : Excluded : Acyclovir prophylaxis herpes within 48 hour prior study entry . Patients meet follow criterion : Successful completion shortterm therapy vesnarinone FDA 234A FDA 234B . Active illicit drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>vesnarinone</keyword>
</DOC>